Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion
ANN-008
Phase 2 other active
Quick answer
Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion for Diabetic Retinopathy, Retinal Vein Occlusion is a Phase 2 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Diabetic Retinopathy, Retinal Vein Occlusion
- Phase
- Phase 2
- Modality
- other
- Status
- active